急性髓系白血病细胞单链DNA适体的体外筛选

目的:筛选识别急性髓系白血病M2型(acute myeloblastic leukemia M2 subtype,AML-M2)CD33+/CD34-细胞的核酸适体(aptamers)。方法:以AML-M2型白血病CD33+/CD34-细胞为靶细胞,正常人CD33+/CD34-细胞为反筛选细胞,采用细胞-指数富集配体系统进化(cell-systematic evolution of ligands by exponential enrichment,C-SELEX)技术,体外反复筛选单链DNA(single strand deoxyribonucleic acid,ssDNA)文库的适体,经聚合酶链式反应(polymerasechain reaction,PCR)扩增产生次级文库。然后将最终轮次的次级ssDNA文库克隆、测序并分析各适体的一级和二级结构。结果:琼脂糖凝胶电泳结果显示:每轮筛选出来的次级ssDNA文库PCR扩增产物均可见到清晰的DNA条带。经过13轮的反复筛选,次级ssDNA文库与细胞结合的荧光强度从2.14%上升到51.12%,至第13轮趋于稳定状态。对30个克隆子序列测定结果显示:22个适体一级结构分别含有AAGTA,TATCT,AGATG和AAATT 4个保守序列,另8个适体无此保守序列。二级结构模拟结果显示:30个适体含有4种不同的茎环、凸环模拟结构。结论:C-SELEX技术可用于急性髓系白血病原代细胞适体的筛选,筛选到的AML-M2型白血病CD33+/CD34-细胞适体有望用于白血病的诊断与治疗。

In vitro selection of single strand deoxyribonucleic acid aptamers binding to cells from patients with acute myeloblastic leukemia

Objective: To screen aptamers binding CD33+/CD34- cells from patients with acute myeloblastic leukemia M2 subtype (AML-M2). Methods: CD33+/CD34- cells from patients with AML-M2 were taken as targeted cells, CD33+/ CD34- cells from normal people were taken as anti-selecting cells, and aptamers in the single strand deoxyribonucleic acid (ssDNA) library were then selected repeatedly by cell-systematic evolution of ligands by exponential enrichment (C-SELEX) technology, and amplified by polymerase chain reaction (PCR) to generate sub-ssDNA library. During the experiment, PCR amplification with fluorescently labeled primer and flow cytometry were performed to analyze the aptamers'enrichment of sub-library, and the final round product of the sub-ssDNA library was cloned. After the sequencing, the primary and secondary structures of the aptamers were analyzed. Results: Electrophoresis indicated that the product of PCR amplification for each round subssDNA library was able to see a clear DNA band in the agarose gel. After 13 rounds of screening, the fluorescence intensity of the sub-ssDNA library binding the cells ranged from 2.14% to 51.12%, reaching a steady state at the 13th round. A total of 30 clones were selected and sequenced, 22 of which contained 1 of the 4 conserved sequences of AAGTA, TATCT, AGATG and AAATT in their primary structure, but the remained eight aptamers contained none of the conserved sequence. Secondary structure analysis indicated that four stem-loops and loop simulation convex structures existed in the aptamers. Conclusion: C-SELEX technology can be used to screen the aptamers binding primary cells from patients with leukemia. The aptamers selected from the CD33+/CD34- cells from the patients of AML-M2 subtype might be used for the diagnosis and treatment for leukemia.